European multicentre study to define disease activity criteria for systemic sclerosis.: II.: Identification of disease activity variables and development of preliminary activity indexes

被引:286
作者
Valentini, G
Della Rossa, A
Bombardieri, S
Bencivelli, W
Silman, AJ
D'Angelo, S
Cerinic, MM
Belch, JF
Black, CM
Bruhlmann, P
Czirják, L
De Luca, A
Drosos, AA
Ferri, C
Gabrielli, A
Giacomelli, R
Hayem, G
Inanc, M
McHugh, NJ
Nielsen, H
Rosada, M
Scorza, R
Stork, J
Sysa, A
van den Hoogen, FHJ
Vlachoyiannopoulos, PJ
机构
[1] Univ Naples 2, Div Rheumatol, I-80131 Naples, Italy
[2] Univ Pisa, I-56100 Pisa, Italy
[3] Univ Manchester, Manchester M13 9PL, Lancs, England
[4] Univ Florence, I-50121 Florence, Italy
[5] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
[6] Royal Free Acad Hosp, London, England
[7] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[8] Univ Pecs, Pecs, Hungary
[9] Univ Ioannina, GR-45110 Ioannina, Greece
[10] Univ Ancona, I-60128 Ancona, Italy
[11] Univ Aquila, I-67100 Laquila, Italy
[12] Univ Paris 07, Paris, France
[13] Istanbul Univ, Istanbul, Turkey
[14] Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England
[15] Hervel Hosp, Rheumatol Unit, Hervel, Denmark
[16] Univ Padua, I-35100 Padua, Italy
[17] Univ Milan, I-20122 Milan, Italy
[18] Univ Lodz, PL-90131 Lodz, Poland
[19] Charles Univ Prague, Prague, Czech Republic
[20] Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands
[21] Natl Tech Univ Athens, GR-10682 Athens, Greece
关键词
D O I
10.1136/ard.60.6.592
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To develop criteria for disease activity in systemic sclerosis (SSc) that are valid, reliable, and easy to use. Methods-Investigators from 19 European centres completed a standardised clinical chart for a consecutive number of patients with SSc. Three protocol management members blindly evaluated each chart and assigned a disease activity score on a semiquantitative scale of 0-10. Two of them, in addition, gave a blinded, qualitative evaluation of disease activity ("inactive to moderately active" or "active to very active" disease). Both these evaluations were found to be reliable. A final disease activity score and qualitative evaluation of disease activity were arrived at by consensus for each patient; the former represented the gold standard for subsequent analyses. The correlations between individual items in the chart and this gold standard were then analysed. Results-A total of 290 patients with SSc (117 with diffuse SSc (dSSc) and 173 with limited SSc (lSSc)) were enrolled in the study. The items (including Delta -factors-that is, worsening according to the patient report) that were found to correlate with the gold standard on multiple regression were used to construct three separate 10-point indices of disease activity: (a) Delta -cardiopulmonary (4.0), Delta -skin (3.0), Delta -vascular (2.0), and Delta -articular/muscular (1.0) for patients with dSSc; (b) Delta -skin (2.5), erythrocyte sedimentation rate (ESR) >30 mm/1st h (2.5), Delta -cardiopulmonary (1.5), Delta -vascular (1.0), arthritis (1.0), hypocomplementaemia (1.0), and scleredema (0.5) for lSSc; (c) Delta -cardiopulmonary (2.0), Delta -skin (2.0), ESR >30 mm/1st h (1.5), total skin score >20 (1.0), hypocomplementaemia (1.0), scleredema (0.5), digital necrosis (0.5), Delta -vascular (0.5), arthritis (0.5), TLCO <80% (0.5) for all patients with SSc. The three indexes were validated by the jackknife technique. Finally, receiver operating characteristic curves were constructed in order to define the value of the index with the best discriminant capacity for "active to very active" patients. Conclusions-Three feasible, reliable, and valid preliminary indices to define disease activity in SSc were constructed.
引用
收藏
页码:592 / 598
页数:7
相关论文
共 37 条
[1]  
*AM RHEUM ASS GLOS, 1982, DICT RHEUM DIS, V2
[2]  
*AM RHEUM ASS GLOS, 1982, DICT RHEUMATIC DIS, V1
[3]   PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[4]  
Belch JJF, 1997, ADV EXP MED BIOL, V428, P1
[5]   THE COMPLEMENT-SYSTEM AND SYSTEMIC-SCLEROSIS [J].
BENBASSAT, C ;
SCHLESINGER, M ;
LUDERSCHMIDT, C ;
VALENTINI, G ;
TIRRI, G ;
SHOENFELD, Y .
IMMUNOLOGIC RESEARCH, 1993, 12 (03) :312-316
[6]  
BLACK CM, 1989, BRIT J RHEUMATOL, V28, P98
[7]  
BLACK CM, 1998, THERAPY SYSTEMIC RHE, P495
[8]  
Black CM, 1993, OXFORD TXB RHEUMATOL, P771
[9]  
BOERS M, 1993, J RHEUMATOL, V20, P552
[10]   STATISTICAL-METHODS FOR ASSESSING OBSERVER VARIABILITY IN CLINICAL MEASURES [J].
BRENNAN, P ;
SILMAN, A .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6840) :1491-1494